Kyle B Zuniga1,2, Shoujun Zhao3, Stacey A Kenfield3, Benjamin Cedars4, Janet E Cowan3, Erin L Van Blarigan3,5, Jeanette M Broering3, Peter R Carroll3, June M Chan3,5. 1. Osher Center for Integrative Medicine, University of California-San Francisco, San Francisco, California. 2. College of Physicians and Surgeons, Columbia University Medical Center, New York, New York. 3. Department of Urology, University of California-San Francisco, San Francisco, California. 4. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania. 5. Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California.
Abstract
PURPOSE: We explored the prevalence and trends of self-reported complementary and alternative medicine use among patients with prostate cancer using CaPSURE™ (Cancer of the Prostate Strategic Urologic Research Endeavor). MATERIALS AND METHODS: A total of 7,989 CaPSURE participants completed questionnaires between 1996 and 2016 on the use of nearly 70 complementary and alternative medicine types. Participants were defined as users if they indicated that they had ever used complementary and alternative medicines. To evaluate trends among 7,696 patients with newly diagnosed prostate cancer we considered complementary and alternative medicine use within 24 months of diagnosis and calculated the percent change in complementary and alternative medicine use between groups defined by the year of diagnosis. RESULTS: Of patients with prostate cancer 56% reported complementary and alternative medicine use on at least 1 questionnaire. Multivitamin and omega-3 fatty acid use was common at 40% and 24% of patients, respectively. Compared to nonusers greater proportions of complementary and alternative medicine users were college educated, had a higher household income and lived in the West and Midwest. Median prostate specific antigen at diagnosis was 5.8 (IQR 4.4-8.4) and 6.2 ng/ml (IQR 4.7-10.1) among users and nonusers, respectively (p <0.01). Between those diagnosed in 1996 to 2000 and 2011 to 2016, complementary and alternative medicine use increased 128% from 24% to 54%. When comparing participants diagnosed in 2006 to 2010 with those diagnosed in 2011 to 2016, a 108% increase was seen in supplemental vitamin D use and a -48% decrease was seen in supplemental vitamin E use. CONCLUSIONS: Many patients with prostate cancer reported complementary and alternative medicine use. Multivitamins and omega-3 fatty acids were commonly ingested and vitamin D use increased dramatically from 2006 to 2010 compared to 2011 to 2016. These data can guide clinical discussions and decision making such as nutritionist referral and help prioritize future research.
PURPOSE: We explored the prevalence and trends of self-reported complementary and alternative medicine use among patients with prostate cancer using CaPSURE™ (Cancer of the Prostate Strategic Urologic Research Endeavor). MATERIALS AND METHODS: A total of 7,989 CaPSURE participants completed questionnaires between 1996 and 2016 on the use of nearly 70 complementary and alternative medicine types. Participants were defined as users if they indicated that they had ever used complementary and alternative medicines. To evaluate trends among 7,696 patients with newly diagnosed prostate cancer we considered complementary and alternative medicine use within 24 months of diagnosis and calculated the percent change in complementary and alternative medicine use between groups defined by the year of diagnosis. RESULTS: Of patients with prostate cancer 56% reported complementary and alternative medicine use on at least 1 questionnaire. Multivitamin and omega-3 fatty acid use was common at 40% and 24% of patients, respectively. Compared to nonusers greater proportions of complementary and alternative medicine users were college educated, had a higher household income and lived in the West and Midwest. Median prostate specific antigen at diagnosis was 5.8 (IQR 4.4-8.4) and 6.2 ng/ml (IQR 4.7-10.1) among users and nonusers, respectively (p <0.01). Between those diagnosed in 1996 to 2000 and 2011 to 2016, complementary and alternative medicine use increased 128% from 24% to 54%. When comparing participants diagnosed in 2006 to 2010 with those diagnosed in 2011 to 2016, a 108% increase was seen in supplemental vitamin D use and a -48% decrease was seen in supplemental vitamin E use. CONCLUSIONS: Many patients with prostate cancer reported complementary and alternative medicine use. Multivitamins and omega-3 fatty acids were commonly ingested and vitamin D use increased dramatically from 2006 to 2010 compared to 2011 to 2016. These data can guide clinical discussions and decision making such as nutritionist referral and help prioritize future research.
Authors: Gary H Lyman; Heather Greenlee; Kari Bohlke; Ting Bao; Angela M DeMichele; Gary E Deng; Judith M Fouladbakhsh; Brigitte Gil; Dawn L Hershman; Sami Mansfield; Dawn M Mussallem; Karen M Mustian; Erin Price; Susan Rafte; Lorenzo Cohen Journal: J Clin Oncol Date: 2018-06-11 Impact factor: 44.544
Authors: JoAnn E Manson; Nancy R Cook; I-Min Lee; William Christen; Shari S Bassuk; Samia Mora; Heike Gibson; David Gordon; Trisha Copeland; Denise D'Agostino; Georgina Friedenberg; Claire Ridge; Vadim Bubes; Edward L Giovannucci; Walter C Willett; Julie E Buring Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: William J Aronson; Naoko Kobayashi; R James Barnard; Susanne Henning; Min Huang; Patricia M Jardack; Bingrong Liu; Ashley Gray; Junxiang Wan; Ramdev Konijeti; Stephen J Freedland; Brandon Castor; David Heber; David Elashoff; Jonathan Said; Pinchas Cohen; Colette Galet Journal: Cancer Prev Res (Phila) Date: 2011-10-25
Authors: Andrew K L Goey; Kim D Mooiman; Jos H Beijnen; Jan H M Schellens; Irma Meijerman Journal: Cancer Treat Rev Date: 2013-02-08 Impact factor: 12.111
Authors: Matthew R Cooperberg; Jeanette M Broering; Mark S Litwin; Deborah P Lubeck; Shilpa S Mehta; James M Henning; Peter R Carroll Journal: J Urol Date: 2004-04 Impact factor: 7.450
Authors: Ted A Skolarus; Andrew M D Wolf; Nicole L Erb; Durado D Brooks; Brian M Rivers; Willie Underwood; Andrew L Salner; Michael J Zelefsky; Jeanny B Aragon-Ching; Susan F Slovin; Daniela A Wittmann; Michael A Hoyt; Victoria J Sinibaldi; Gerald Chodak; Mandi L Pratt-Chapman; Rebecca L Cowens-Alvarado Journal: CA Cancer J Clin Date: 2014-06-10 Impact factor: 508.702
Authors: Scott M Lippman; Eric A Klein; Phyllis J Goodman; M Scott Lucia; Ian M Thompson; Leslie G Ford; Howard L Parnes; Lori M Minasian; J Michael Gaziano; Jo Ann Hartline; J Kellogg Parsons; James D Bearden; E David Crawford; Gary E Goodman; Jaime Claudio; Eric Winquist; Elise D Cook; Daniel D Karp; Philip Walther; Michael M Lieber; Alan R Kristal; Amy K Darke; Kathryn B Arnold; Patricia A Ganz; Regina M Santella; Demetrius Albanes; Philip R Taylor; Jeffrey L Probstfield; T J Jagpal; John J Crowley; Frank L Meyskens; Laurence H Baker; Charles A Coltman Journal: JAMA Date: 2008-12-09 Impact factor: 56.272
Authors: F L Bishop; A Rea; H Lewith; Y K Chan; J Saville; P Prescott; E von Elm; G T Lewith Journal: Prostate Cancer Prostatic Dis Date: 2010-10-19 Impact factor: 5.554
Authors: Maria G Grammatikopoulou; Konstantinos Gkiouras; Stefanos Τ Papageorgiou; Ioannis Myrogiannis; Ioannis Mykoniatis; Theodora Papamitsou; Dimitrios P Bogdanos; Dimitrios G Goulis Journal: Nutrients Date: 2020-09-29 Impact factor: 5.717